New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
10:21 EDTFIO, MTOR, VRTX, APOL, SBGI, OHRP, IRM, UNXL, ACHNOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN SBGI MTOR UNXL APOL FIO IRM CBS
News For OHRP;VRTX;ACHN;SBGI;MTOR;UNXL;APOL;FIO;IRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 5, 2015
06:12 EDTACHNAchillion plans to initiate Sparta doublet regimen clinical trial in 1H15
Plans to initiate in the first half of 2015 a clinical trial with ACH-3422 in combination with ACH-3102 for patients with treatment-na´ve genotype 1 HCV for treatment durations of 6, 8 and 12 weeks. SVR4 results are expected in the second half of 2015. Plans to initiate during the first quarter a Phase 1 proof-of-concept trial evaluating the anti-viral activity of ACH-3422 for HCV genotypes 2 and 3. Results are anticipated during the second quarter of 2015. Expects to initiate during the first half of 2015 a proxy triplet trial evaluating ACH-3102 and sovaprevir with sofosbuvir for a treatment duration of 4 weeks. SVR4 results are expected in the second half of 2015; and expects to initiate by the end of 2015 a pharmacokinetic and viral kinetic study of ACH-3422, ACH-3102 and sovaprevir in patients with treatment-na´ve genotype 1 HCV. Expects to nominate a novel orally-administered complement factor D inhibitor and advance into a phase I clinical trial by the end of 2015.
06:11 EDTACHNAchillion sees FY15 EPS (95c), consensus (83c)
Subscribe for More Information
06:11 EDTACHNAchillion reports Q4 EPS (21c), consensus (18c)
Subscribe for More Information
March 4, 2015
10:01 EDTACHNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:35 EDTACHNAchillion initiated with an Underweight at Barclays
Barclays started shares of Achillion with an Underweight rating and $8 price target citing the company's lateness to the hepatitis C market as well as competition in the space.
March 2, 2015
10:00 EDTOHRPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:22 EDTOHRPOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Amira Nature Foods (ANFI), up 8.6%... Stratasys (SSYS), up 3.6%... Magnum Hunter (MHR), up 3%. ALSO HIGHER: Mavenir Systems (MVNR), up 19.1% after Mitel (MITL) agrees to acquire Mavenir Systems for $560M... Athersys (ATHX), up 19.7% following license agreement and collaboration with Chugai... OHR Pharmaceutical (OHRP), up 11.4% following additional positive data from OHR-102 IMPACT study... NXP Semiconductors (NXPI), up 14% following merger agreement with Freescale Semiconductor (FSL). Freescale Semiconductor is up 9.1%... Mast Therapeutics (MSTX), up 7.7% following positive results from Vepoloxamer study. DOWN AFTER EARNINGS: JinkoSolar (JKS), down 4.7%... Scorpio Tankers (STNG), down 4.5%. ALSO LOWER: Lumber Liquidators (LL), down 24.2% following CBS' 60 Minutes says that the company is linked to health and safety violations... Aruba Networks (ARUN), down 1.7% after HP (HPQ) confirms deal to acquire Aruba Networks for $24.67... Pacira Pharmaceuticals (PCRX), down 14.4% after receiving complete response letter from FDA for sNDA in use of Exparel... 500.com (WBAI), down 14.4% after announcing that temporary suspension will adversely impact financial results.
07:59 EDTOHRPOhr Pharmaceutical announces additional positive data from OHR-102 IMPACT study
Subscribe for More Information
07:47 EDTOHRPOhr Pharmaceutical initiated with an Outperform at Cowen
Subscribe for More Information
February 26, 2015
16:14 EDTUNXLUni-Pixel reports Q4 EPS (63c), one estimate (45c)
Subscribe for More Information
10:56 EDTAPOLOptions with increasing implied volatility
Subscribe for More Information
08:19 EDTOHRPOhr Pharmaceutical appoints Avner Ingerman, M.D. as Chief Clinical Officer
Subscribe for More Information
February 25, 2015
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 24, 2015
10:45 EDTAPOLApollo Education calls active on renewed takeover chatter
Apollo Education March 28, 29 and April 30 calls are active on total call volume of 4,900 contracts (200 puts) on renewed takeover chatter. March call option implied volatility is at 28, April is at 37, May is at 35; compared to its 26-week average of 33 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:35 EDTAPOLRumor: Apollo Education moves up on renewed takeover chatter
Subscribe for More Information
10:34 EDTACHNAchillion March calls active on renewed takeover chatter
Achillion March 14 and April 15 calls are active on total call volume of 1,600 contracts (100 puts) on renewed takeover chatter. February weekly call option implied volatility is at 82, March and April is at 79, June is at 81; compared to its 10-week average of 81 according to Track Data. Active call volume suggests traders taking positions for large near term price movement.
10:22 EDTACHNRumor: Achillion moves positive on renewed takeover chatter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use